Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.

Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC, Lai PB, Cai Z, Peng J, Leng X, Poon RT, Luk JM.

Ann Surg Oncol. 2010 Sep;17(9):2518-25. doi: 10.1245/s10434-010-1038-8. Epub 2010 Mar 31.

2.

Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.

Wu C, Wang Z, Liu L, Zhao P, Wang W, Yao D, Shi B, Lu J, Liao P, Yang Y, Zhu L.

J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24.

PMID:
18823443
3.

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.

Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586.

4.

SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.

Geng X, Wang F, Li YG, Zhu GP, Zhang WM.

J Exp Clin Cancer Res. 2007 Dec;26(4):505-8.

PMID:
18365545
5.

Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.

Wu FX, Wang Q, Zhang ZM, Huang S, Yuan WP, Liu JY, Ban KC, Zhao YN.

Cancer Lett. 2009 Jul 8;279(2):163-70. doi: 10.1016/j.canlet.2009.01.034. Epub 2009 Mar 5.

PMID:
19268439
6.

Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.

Wang JX, Zhang B, Yu JK, Liu J, Yang MQ, Zheng S.

Chin Med J (Engl). 2005 Aug 5;118(15):1278-84.

PMID:
16117882
7.

Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature.

Cao XL, Li H, Yu XL, Liang P, Dong BW, Fan J, Li M, Liu FY.

PLoS One. 2013 Dec 13;8(12):e82448. doi: 10.1371/journal.pone.0082448. eCollection 2013.

8.

New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.

Göbel T, Vorderwülbecke S, Hauck K, Fey H, Häussinger D, Erhardt A.

World J Gastroenterol. 2006 Dec 21;12(47):7604-12.

9.
10.

Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.

Liao J, Zhang R, Qian H, Cao L, Zhang Y, Xu W, Li J, Wu M, Yin Z.

Biochem Biophys Res Commun. 2012 Apr 6;420(2):308-14. doi: 10.1016/j.bbrc.2012.02.155. Epub 2012 Mar 7.

PMID:
22425980
11.

Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.

Wang N, Cao Y, Song W, He K, Li T, Wang J, Xu B, Si HY, Hu CJ, Li AL.

J Gastroenterol Hepatol. 2014;29(7):1544-50. doi: 10.1111/jgh.12545.

PMID:
24612022
12.

Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.

Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO, Tsubouchi H.

Hepatology. 2007 Apr;45(4):948-56.

PMID:
17393466
13.

Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.

Cui J, Kang X, Dai Z, Huang C, Zhou H, Guo K, Li Y, Zhang Y, Sun R, Chen J, Li Y, Tang Z, Uemura T, Liu Y.

J Cancer Res Clin Oncol. 2007 Nov;133(11):825-34. Epub 2007 May 22.

PMID:
17516088
14.

Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.

He QY, Zhu R, Lei T, Ng MY, Luk JM, Sham P, Lau GK, Chiu JF.

J Cell Biochem. 2008 Feb 15;103(3):740-52.

PMID:
17557278
15.

Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis.

Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ.

Br J Cancer. 2006 Jan 30;94(2):287-92.

16.

Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.

Mossad NA, Mahmoud EH, Osman EA, Mahmoud SH, Shousha HI.

Tumour Biol. 2014 Nov;35(11):11559-64. doi: 10.1007/s13277-014-2467-y. Epub 2014 Aug 17.

PMID:
25129443
18.

The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.

Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, Stadheim LM, Aderca I, Moser CD, Nagorney DM, LaRusso NF, de Groen PC, Menon KV, Lazaridis KN, Gores GJ, Charlton MR, Roberts RO, Therneau TM, Katzmann JA, Roberts LR.

Clin Gastroenterol Hepatol. 2007 Mar;5(3):394-402; quiz 267.

19.

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.

Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group.

Gastroenterology. 2010 Feb;138(2):493-502. doi: 10.1053/j.gastro.2009.10.031. Epub 2009 Oct 20.

20.

Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry coupled with an artificial neural network model for the diagnosis of hepatocellular carcinoma.

Hu Q, Huang Y, Wang Z, Tao H, Liu J, Yan L, Wang K.

Hepatogastroenterology. 2012 Sep;59(118):1902-6. doi: 10.5754/hge11771.

PMID:
22193438

Supplemental Content

Support Center